pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Approval · news · pharmadog
← back to Approval
News · Approval
1,551
stories
4d
Summit shares fall as FDA rejects closely watched PD-1/VEGF drug
biopharma dive
4d
CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trial
biopharma dive
4d
J&J bets $2.2B on Ollin’s vision loss drug
biopharma dive
4d
J&J pays $2.2B upfront for Ollin, taps Blackstone to fund eye disease trial
biospace
4d
FDA’s Summit rejection puts PD-1xVEGF class on notice to establish overall survival
biospace
4d
Novo’s CagriSema drives more than 20% weight loss at lower doses
biospace
5d
CG preps new, expanded bladder cancer plans with FDA after ph. 3 win
fiercebiotech
5d
Helus' chemically modified psychedelic hits key goals in phase 3 depression trial
fiercebiotech
5d
BioSpace 40 Under 40 winners Paull, Zhang let patients with rare disease lead the way at BridgeBio
biospace
5d
STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics
stat
5d
Summit's PD-1xVEGF rejected by FDA in lung cancer
biospace
7d
STAT+: Doctors have questions about the Watchman. Boston Scientific has a sales pitch.
stat
7d
Moderna readies commercial cancer vaccine production ahead of FDA filing
endpoints
7d
Milestone cuts 20% of staff as Cardamyst sales hit $1M in Q3
endpoints
7d
Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earnings
biospace
7d
STAT+: Up and down the ladder: The latest comings and goings
stat
7d
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
fiercebiotech
7d
Novo submits sickle cell drug; Flagship, Gates Foundation deepen ties
biopharma dive
7d
STAT+: Pharmalittle: We’re reading about Lilly conflict questions, a DEA OK for a narcolepsy pill, and more
stat
7d
Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026
biospace
8d
Rezolute gets an uplift from phase 3 tumor hyperinsulinism win ahead of FDA meeting
fiercebiotech
8d
Sanofi-backed Windward hits $225M IPO goal, as Rezera delays listing over ‘market conditions’
fiercebiotech
8d
FDA's speedy voucher program is dead — report
endpoints
8d
Deep dive: Cardiovascular calamities and catalysts
biospace
8d
Eros Apothecary Issues Recall of Candy Power For Man Organic Honey Due to Undeclared Tadalafil
fda recalls
8d
Neurosterix nabs $105M, recruits Karuna veterans for schizophrenia push
biospace
8d
Bristol Myers research chief to depart in ‘evolution’ of company’s structure
biopharma dive
8d
FDA’s commissioner voucher program reportedly shuttered ahead of Senate vote on Overton
biospace
8d
Chutes & Ladders—Bristol Myers' research chief out amid R&D reorganization
fiercebiotech
8d
STAT+: Pharmalittle: We’re reading about FDA shelving fast-track review, a Canadian importer arrested, and more
stat
← prev
page 3 of 52
next →